Abstract:Puerarin, a monomer of traditional Chinese medicine, is a key component of Pueraria radix. Both clinical and experimental researches demonstrated that puerarin has therapeutic effects on Parkinson's disease (PD). Puerarin's pharmacological mechanisms include: 1) Anti-apoptosis. Puerarin inhibits cell apoptosis through the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/protein kinase B (Akt) and c-Jun N-terminal kinase (JNK) signaling pathways. Puerarin also exerts a hormone-like effect against cell apoptosis; 2) Anti-oxidative stress injury. Puerarin inhibits the Nrf2 nuclear exclusion through the GSK-3β/Fyn pathway to promote the Nrf2 accumulation in the nucleus, and then promotes the antioxidant synthesis through the Nrf2/ARE signaling pathway to protect against oxidative stress; 3) Neuroprotective effects by intervening in the ubiquitin-proteasome system (UPS) and autophagy-lysosomal pathway (ALP). Puerarin significantly enhances the activity of chaperone-mediated autophagy (CMA), which downregulates the expression of α-synuclein, reduces its accumulation, and thus improves the function of damaged neurons. Additionally, puerarin increases proteasome activity and decreases ubiquitin-binding proteins, thereby preventing toxic accumulation of intracellular proteins; 4) Alleviating inflammatory response. Puerarin inhibits the conversion of microglia to the M1 phenotype while inducing the transition of microglia to the M2 phenotype. Furthermore, puerarin promotes the secretion of anti-inflammatory factor and inhibits the expression of pro-inflammatory factors; 5) Increasing the levels of dopamine and its metabolites. Puerarin could increase the levels of dopamine, homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC) in the striatum; 6) Promoting neurotrophic factor expression and neuronal repair. Puerarin increases the expression of glial cell-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), thereby exerting a neuroprotective effect. Moreover, the regulation of the gut microbiota by puerarin may be a potential mechanism for the treatment of PD. The current review discusses the molecular mechanisms of puerarin, which may provide insight into the active components of traditional Chinese medicine in the treatment of PD.

Oral Delivery of Puerarin Nanocrystals to Improve Brain Accumulation and Anti-Parkinsonian Efficacy.

Nanoparticles Mediating the Sustained Puerarin Release Facilitate Improved Brain Delivery to Treat Parkinson's Disease

Enhancement of Oral Bioavailability and Anti-Parkinsonian Efficacy of Resveratrol Through a Nanocrystal Formulation

Improvement in Solubility and Bioavailability of Puerarin by Mechanochemical Preparation

Enhancement of Oral Bioavailability of Puerarin by Polybutylcyanoacrylate Nanoparticles

Enhanced Oral Bioavailability of Acetylpuerarin by Poly(lactide-Co-glycolide) Nanoparticles Optimized Using Uniform Design Combined with Response Surface Methodology

Preparation and Evaluation of Puerarin-loaded PLGA Nanoparticles for Improving Oral Bioavailability in SD Rats

Polymeric Nanoparticles-Based Brain Delivery with Improved Therapeutic Efficacy of Ginkgolide B in Parkinson’s Disease

Localized Delivery of Curcumin into Brain with Polysorbate 80-Modified Cerasomes by Ultrasound-Targeted Microbubble Destruction for Improved Parkinson's Disease Therapy

Highly Stabilized Nanocrystals Delivering Ginkgolide B in Protecting Against the Parkinson’s Disease

Formulation and Pharmacokinetics Evaluation of Puerarin Nanocrystals for Intravenous Delivery

Pharmacological mechanisms of puerarin in the treatment of Parkinson's disease: An overview

Enhancing both oral bioavailability and brain penetration of puerarin using borneol in combination with preparation technologies

Preparation, characterization and bioavailability of oral puerarin nanoparticles by emulsion solvent evaporation method

Formulation of 20(S)-protopanaxadiol nanocrystals to improve oral bioavailability and brain delivery

Enhanced Oral Absorption and Therapeutic Effect of Acetylpuerarin Based on D-Alpha-Tocopheryl Polyethylene Glycol 1000 Succinate Nanoemulsions

Preparation of cubic liquid crystal nanoparticles of puerarin and its protective effect on ischemic stroke

Plant-derived Exosomes As Cell Homogeneous Nanoplatforms for Brain Biomacromolecules Delivery Ameliorate Mitochondrial Dysfunction Against Parkinson’s Disease

Nir-Ii-Activated Yolk-Shell Nanostructures As An Intelligent Platform For Parkinsonian Therapy

Small-Sized mPEG-PLGA Nanoparticles of Schisantherin A with Sustained Release for Enhanced Brain Uptake and Anti-Parkinsonian Activity

Localized Delivery of Curcumin-Loaded Nanoparticles to the Brain for Treatment of Parkinson'S Disease Using Focused Ultrasound